Primary Sclerosing Cholangitis: Gender Effects in Valencia's Low-Prevalence Region
- PMID: 38517562
- DOI: 10.1007/s10620-024-08368-y
Primary Sclerosing Cholangitis: Gender Effects in Valencia's Low-Prevalence Region
Abstract
Background and aims: Recent studies point out to epidemiological changes in primary sclerosing cholangitis (PSC). Our aims were to determine in PSC patients followed in several centers in a Mediterranean geographic area: (i) changes in baseline features and (ii) effect of gender on clinical course.
Methods: Retrospective multicenter study of PSC patients treated in 8 hospitals in a Mediterranean area between 2000 and 2021. Charts were reviewed compiling demographic, clinical, radiological, and histological variables.
Results: Cohort of 112 PSC patients included, 42% women, 70% diagnosed after 2010. Women were increasingly diagnosed in recent cohorts. The median time from diagnosis to the combined endpoint liver transplantation (Lt) and/or death was 6.9 years. Asthenia at diagnosis (p = 0.009) was associated with lower transplant-free survival, while diagnosis before 2005 was associated with greater LT-free survival (p < 0.001). By Cox regression, LT-free survival was not influenced by age, sex, or cirrhosis at the time of diagnosis. Women were found to have less jaundice at diagnosis (2 vs 14%; p = 0.013), higher prevalence of ANA antibodies (43.9 vs 15.7%; p = 0.003), and lower GGT levels at diagnosis (GGT 123 vs 209U/L; p = 0.014) than men.
Conclusion: In an area traditionally considered to have low prevalence, the prevalence of affected women surpasses expectations based on existing literature. There appear to be gender-related variations in the presentation of the condition, highlighting the need for confirmation through larger-scale studies.
Keywords: Inflammatory bowel disease; Liver transplantation; Primary sclerosing cholangitis; Sex.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Berdal JE, Ebbesen J, Rydning A. [Incidence and prevalence of autoimmune liver diseases] Insidens og prevalens av autoimmune leverlidelser. Tidsskr Nor Laegeforen 1998;118:4517e9.
-
- Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;9:1587–1599. https://doi.org/10.1016/S0140-6736(13)60096-3 . - DOI
-
- Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181–1188. https://doi.org/10.1016/j.jhep.2011.10.025 . - DOI - PubMed
-
- Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver 2018;15:17–29. https://doi.org/10.5009/gnl16510 . - DOI
-
- Liu JZ, Hov JR, Folseraas T et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670–675. https://doi.org/10.1038/ng.2616 . - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
